ReviewClinics in liver disease2022
Hyponatremia in Cirrhosis.
Review in Clinics in liver disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Circulating copeptin level and the clinical prognosis of patients with chronic liver disease.World journal of gastroenterology · 2023Pooled it
- Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial.Hepatology international · 2026Trial
- Biochemical characteristics associated with spironolactone use in hospitalized patients with hypotonic hyponatraemia.Annals of medicine · 2026Article
- Determinants of Early Renal Function Recovery After TIPS in Patients With Portal Hypertension.The Kaohsiung journal of medical sciences · 2026Article
- KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications 2026.Clinical and molecular hepatology · 2026Article
- Article
- Unique Clinically Relevant Prognostic Indicators After TIPS Placement in Cirrhosis Patients with Pre-Existing Kidney Disease.Journal of clinical medicine · 2026Article
- Association between serum sodium and the risk of sepsis-related liver injury: a cross-sectional study based on the MIMIC-IV database.BMC infectious diseases · 2025Article
- Article
- Tolvaptan versus other interventions for hyponatraemia in people with cirrhosis.The Cochrane database of systematic reviews · 2025Article
- Alcoholic Liver Disease and Systemic Inflammatory Response Syndrome: Mortality Prediction Using Biomarkers and Clinical Scores.Journal of clinical medicine · 2025Article
- Hypochloremia is an underutilised prognostic marker in patients with advanced liver cirrhosis and liver failure.World journal of hepatology · 2025Review
- Alcohol-Associated Hepatitis: Short- and Long-Term Management.Digestive diseases and sciences · 2025Review
- Implications of Dysnatremia and Endocrine Disturbances in COVID-19 Patients.International journal of molecular sciences · 2024Review
- Effects of donors' and recipients' preoperative serum sodium on the prognosis of liver transplantation.Scientific reports · 2024Article
- Hyponatremia Prevalence in Decompensated Chronic Liver Disease: Insights from a Tertiary Care Hospital.Cureus · 2024Article
- [Consensus recommendations on the diagnosis and treatment of hyponatremia from the Austrian Society for Nephrology 2024].Wiener klinische Wochenschrift · 2024Article
- Correspondence on Letter regarding "Evidence-based hyponatremia management in liver disease".Clinical and molecular hepatology · 2023Article
- Hyponatremia Demystified: Integrating Physiology to Shape Clinical Practice.Advances in kidney disease and health · 2023Review
- Effects of Short-Term Human Albumin Infusion for the Prevention and Treatment of Hyponatremia in Patients with Liver Cirrhosis.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Hyponatremia is the most common electrolyte disorder encountered in clinical practice, and it is a common complication of cirrhosis reflecting an increase in nonosmotic secretion of arginine vasopressin as a result of of the circulatory dysfunction that is characteristic of advanced liver disease. Hyponatremia in cirrhosis has been associated with poor clinical outcomes including increased risk of morbidity and mortality, poor quality of life, and heightened health care utilization. Despite this, the treatment of hyponatremia in cirrhosis remains challenging as conventional therapies such as fluid restriction are frequently ineffective. In this review, we discuss the epidemiology, clinical outcomes, pathogenesis, etiology, evaluation, and management of hyponatremia in cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.